Cargando…

Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis

BACKGROUND: Eye drops containing 0.1% hyaluronic acid (HA) and 0.5% carboxymethylcellulose (CMC) applied one drop three times a day per affected eye were compared in patients with moderate keratitis or keratoconjunctivitis related to dry eye disease (DED). PATIENTS AND METHODS: This was a prospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groß, Dorothea, Childs, Marc, Piaton, Jean-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001744/ https://www.ncbi.nlm.nih.gov/pubmed/29928109 http://dx.doi.org/10.2147/OPTH.S161578

Ejemplares similares

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
por: Groß, Dorothea, et al.
Publicado: (2017)

Combination of 0.05% Azelastine and 0.1% Tacrolimus Eye Drops in Children With Vernal Keratoconjunctivitis: A Prospective Study
por: Chen, Minjie, et al.
Publicado: (2021)

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
por: Park, Yuli, et al.
Publicado: (2017)

Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye
por: You, In Cheon, et al.
Publicado: (2018)

Comparing the efficacy of sodium hyaluronate eye drops and carboxymethylcellulose eye drops in treating mild to moderate dry eye disease
por: Salim, Sreelakshmi, et al.
Publicado: (2023)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

Safety and Efficacy of a Preservative-Free Artificial Tear Containing Carboxymethylcellulose and Hyaluronic Acid for Dry Eye Disease: A Randomized, Controlled, Multicenter 3-Month Study
por: Aragona, Pasquale, et al.
Publicado: (2020)

Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye
por: Labetoulle, M, et al.
Publicado: (2017)

Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye
por: Labetoulle, M, et al.
Publicado: (2017)

Efficacy of Carboxymethylcellulose and Hyaluronate in Dry Eye Disease: A Systematic Review and Meta-Analysis
por: Song, Jae Kyeong, et al.
Publicado: (2017)

Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis
por: Okumus, Seydi, et al.
Publicado: (2012)

Sodium hyaluronate 0.30% ocular gel versus sodium hyaluronate 0.18% eye drop in the treatment of moderate to severe dry eye disease
por: Calonge, Margarita, et al.
Publicado: (2022)

A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome
por: Lee, Ji Eun, et al.
Publicado: (2022)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis
por: Saha, Bhawesh Chandra, et al.
Publicado: (2023)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

Management of Post-LASIK Dry Eye with Intense Pulsed Light in Combination with 0.1% Sodium Hyaluronate and Heated Eye Mask
por: Wu, Yi, et al.
Publicado: (2021)

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities
por: Jin, Rujun, et al.
Publicado: (2021)

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment
por: Geerling, Gerd, et al.
Publicado: (2022)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Effectiveness of Topical Cyclosporin-A 0.1% Compared to Combined Topical Cyclosporin-A 0.1% with Topical Sodium Hyaluronate on Interleukin-6 Levels in the Tears of Patients with Dry Eye Disease
por: Priani, Desti, et al.
Publicado: (2023)

Comparison of the Efficacy of Carboxymethylcellulose 0.5%, Hydroxypropyl-guar Containing Polyethylene Glycol 400/Propylene Glycol, and Hydroxypropyl Methyl Cellulose 0.3% Tear Substitutes in Improving Ocular Surface Disease Index in Cases of Dry Eye
por: Maharana, Prafulla K., et al.
Publicado: (2017)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

Magnetocaloric Properties of Mn(1.1)Fe(0.9)P(0.5)As(0.5−x)Ge(x) (0 ≤ x ≤ 0.1) Compounds
por: Wlodarczyk, Patryk, et al.
Publicado: (2017)

A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye
por: Xu, Wenhao, et al.
Publicado: (2023)

Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease
por: Bai, Run, et al.
Publicado: (2022)

Efficacy of hyaluronic acid 0.3%, cyanocobalamin, electrolytes, and P-Plus in menopause patients with moderate dry eye disease
por: De-Hita-Cantalejo, Concepción, et al.
Publicado: (2021)

Pressure Dependence of Superconducting Properties, Pinning Mechanism, and Crystal Structure of the Fe(0.99)Mn(0.01)Se(0.5)Te(0.5) Superconductor
por: Murugesan, Kannan, et al.
Publicado: (2021)

Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial
por: Chen, Minjie, et al.
Publicado: (2022)

Recurrent microbial keratitis in eyes with keratoconjunctivitis sicca with coexisting ocular surface pathology
por: Nanavaty, Mayank A., et al.
Publicado: (2014)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease
por: Muñoz-Villegas, Patricia del Carmen, et al.
Publicado: (2023)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

Electrical, dielectric properties and study of AC electrical conduction mechanism of Li(0.9)□(0.1)NiV(0.5)P(0.5)O(4)
por: Rahal, A., et al.
Publicado: (2018)

Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children
por: Bourcier, Tristan, et al.
Publicado: (2022)

Clinical Outcomes of Topical 0.1% Ciclosporin Cationic Emulsion Used on Label in Children with Vernal Keratoconjunctivitis
por: Giannaccare, Giuseppe, et al.
Publicado: (2023)

Tranexamic Acid and Hyaluronate/Carboxymethylcellulose Create Cell Injury
por: Yıldız, Elif, et al.
Publicado: (2014)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella, Pierre-Jean, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9v6p0ie5us99pqo73q4m1na5bj